Fig. 1: Illustration of level of actionability of molecular alterations per patient. | British Journal of Cancer

Fig. 1: Illustration of level of actionability of molecular alterations per patient.

From: Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing

Fig. 1

Some tumours harboured multiple actionable alterations. Actionability of microsatellite instability and high tumour mutational burden/load are expressed in OncoKb level of evidence, since these are no biomarkers for targeted therapy. The CDKN2A mutations entail homozygous deletions. In Table 2 the exact mutations and therapy consequences are specified. AMP amplification, ESCAT ESMO Scale of Clinical Actionability for molecular Targets, HRD homologous recombinant deficient, HZD homozygous deletion, MSI microsatellite instability.

Back to article page